Immunomedics, inc. (IMMU)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11
ASSETS
Current Assets:
Cash and cash equivalents

536,295

608,628

364,654

427,909

437,935

492,860

580,594

612,057

306,746

60,960

42,959

43,394

21,898

5,011

8,464

13,203

11,209

13,716

11,785

13,452

16,063

2,848

5,445

6,961

4,989

6,809

14,643

41,326

47,797

21,399

25,520

32,838

39,050

16,334

20,650

27,097

Marketable securities

4,325

4,550

4,550

4,741

4,741

4,941

4,941

26,745

52,046

78,788

96,675

111,508

24,071

41,602

24,570

37,424

50,369

62,328

73,703

86,165

90,129

18,413

26,541

34,871

15,941

20,024

20,082

0

-

-

-

-

-

-

-

-

Receivable from UCB

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30,000

-

-

Accounts receivable, net of allowances of $0 at March 31, 2020 and December 31, 2019

0

295

-

-

-

0

0

46

195

343

427

489

820

187

584

513

590

409

489

345

598

551

555

674

714

716

399

622

517

547

638

659

618

777

570

736

Inventory

-

-

-

-

-

-

-

0

-

43

527

600

685

737

329

350

170

490

539

584

624

676

732

778

823

886

973

1,030

1,147

921

478

415

499

579

691

289

Other receivables

-

-

-

-

-

-

-

-

-

-

27

-

111

4

-

236

270

26

85

857

185

101

300

303

77

201

938

627

1,124

383

523

389

659

570

2,029

974

Prepaid expenses

17,315

21,818

7,560

8,296

4,868

5,354

-

3,803

4,276

4,738

5,109

891

763

1,042

1,794

1,038

1,562

1,490

1,725

1,136

1,637

1,554

1,842

1,614

1,060

806

1,227

432

798

933

902

582

705

716

852

514

Other current assets

3,788

3,413

1,313

1,313

1,313

1,348

8,479

5,729

5,894

3,720

1,637

436

140

230

358

183

270

315

649

945

378

381

104

180

74

718

241

1,175

183

16

18

593

656

60

161

644

Total current assets

561,723

638,704

378,077

442,259

448,857

504,503

594,014

648,380

369,158

148,593

147,363

157,298

48,491

48,816

36,101

52,951

64,443

78,776

88,976

103,487

109,615

24,527

35,523

45,384

23,680

30,164

38,506

45,215

51,569

24,201

28,082

35,479

42,191

49,038

24,956

30,257

Property and equipment, net of accumulated depreciation and amortization of $8,907 and $7,925 at March 31, 2020 and December 31, 2019, respectively

32,150

32,762

33,386

35,177

35,448

23,469

18,587

15,733

10,669

7,300

5,965

5,245

4,168

4,277

4,477

3,969

3,167

3,136

2,763

2,241

2,065

2,053

2,086

1,895

1,980

1,986

2,074

2,086

2,175

2,243

2,385

2,527

2,730

3,023

3,281

3,456

Value of life insurance policies

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

-

176

176

176

562

603

599

594

611

606

602

598

609

600

590

581

Other long-term assets

233

256

267

249

269

68

61

60

60

60

30

30

30

30

30

30

30

50

50

30

152

30

30

30

30

30

30

30

30

30

30

30

30

30

30

30

Total Assets

594,106

671,722

411,730

477,685

484,574

528,040

612,662

664,173

379,887

155,953

153,359

162,573

52,689

53,124

40,608

56,950

67,641

81,964

91,791

105,779

111,833

26,787

37,815

47,486

26,253

32,784

41,210

47,927

54,386

27,081

31,100

38,635

45,561

52,691

28,858

34,324

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable and accrued expenses

59,268

60,860

54,596

38,967

53,926

31,722

33,710

31,664

23,196

19,993

33,397

31,367

19,597

14,099

14,118

15,188

13,535

14,946

11,985

11,808

8,824

8,951

9,338

6,886

4,477

2,839

3,713

3,950

6,920

5,661

4,999

2,982

5,506

5,921

4,890

5,548

Liability related to sale of future royalties - current

7,491

3,455

3,141

5,314

2,657

0

4,482

3,009

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability - current

346

337

316

271

298

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible senior notes, net

0

7,106

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant liabilities

-

-

-

-

-

-

5,979

8,973

70,331

97,926

165,842

90,706

65,199

14,543

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total current liabilities

67,105

71,758

58,053

44,552

56,881

31,722

44,171

43,740

93,621

118,045

199,394

122,244

84,989

28,860

14,325

15,423

13,801

15,216

12,293

12,079

9,055

9,179

9,582

7,126

4,726

3,127

3,978

6,731

9,477

5,661

4,999

3,164

5,506

5,921

4,890

5,548

Convertible senior notes, net

-

-

7,093

7,081

7,068

7,055

19,799

19,763

19,726

19,689

19,653

98,084

97,901

97,719

97,536

97,354

97,171

96,989

96,807

96,624

96,442

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Liability related to sale of future royalties - non-current

267,215

257,769

248,176

236,354

228,600

221,295

207,280

198,998

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenues

65,000

65,000

65,000

65,000

-

0

0

94

93

125

154

171

192

218

206

235

265

269

307

271

230

228

243

240

248

288

264

2,780

2,557

-

-

182

-

-

-

-

Lease liability - non-current

9,875

9,965

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-recourse debt

-

-

-

-

-

-

-

-

182,216

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest expense on non-recourse debt

-

-

-

-

-

-

-

-

10,626

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other Liabilities, Noncurrent

-

-

10,052

10,138

10,221

2,100

2,097

1,986

1,878

1,768

1,699

1,709

1,717

1,726

1,724

1,699

1,674

1,649

1,624

1,599

1,574

1,550

1,525

1,500

1,475

1,450

1,425

1,400

1,375

1,350

1,326

1,301

1,276

1,251

1,209

1,134

Total Liabilities

409,195

404,492

388,374

363,125

302,770

262,191

273,347

264,487

308,068

-

-

222,037

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Commitments and Contingencies (Note 11)

-

-

-

-

-

-

0

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Stockholders' Equity:
Convertible preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at March 31, 2020 and December 31, 2019

0

0

0

0

0

0

-

0

-

-

-

10

0

0

0

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Common Stock, Value, Issued

2,139

2,125

1,920

1,920

1,915

1,905

1,871

1,868

1,672

1,613

1,520

1,103

1,096

1,060

959

958

948

947

946

945

934

932

931

931

835

832

831

828

827

757

756

755

755

755

754

754

Capital contributed in excess of par

1,590,185

1,579,205

1,235,930

1,232,575

1,224,066

1,219,237

1,203,025

1,194,998

750,391

659,467

573,137

462,666

336,782

334,187

312,093

311,320

307,907

307,165

306,183

305,229

302,180

301,454

300,554

300,080

269,461

268,084

266,855

265,688

265,002

249,779

249,120

248,737

248,115

247,617

245,445

245,023

Treasury stock, at cost: 119,621 shares at March 31, 2020 and December 31, 2019

2,095

2,095

2,095

2,095

2,095

824

1,092

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

458

Accumulated deficit

-1,403,453

-1,310,406

-1,210,798

-1,116,506

-1,040,553

-953,216

-859,717

-795,548

-678,519

-642,973

-640,455

-521,711

-468,456

-409,150

-384,702

-368,504

-352,603

-338,607

-324,861

-309,468

-297,067

-285,311

-273,876

-261,465

-249,618

-240,113

-231,240

-226,039

-221,597

-229,862

-224,470

-214,658

-209,571

-202,305

-222,999

-217,898

Accumulated other comprehensive loss

-802

-568

-601

-365

-560

-351

-334

-353

-457

-401

-343

-303

-126

-79

-127

-132

-113

-277

-109

-161

-243

-6

79

261

295

296

229

161

115

182

140

80

196

136

216

394

Total Immunomedics, Inc. stockholders' equity

185,974

268,261

24,356

115,529

182,773

266,751

343,753

400,507

72,629

17,247

-66,599

-58,693

-131,162

-74,439

-72,235

-56,816

-44,320

-31,230

-18,299

-3,912

5,345

16,610

27,231

39,349

20,515

28,642

36,216

40,180

43,890

20,398

25,089

34,456

39,036

45,745

22,959

27,815

Noncontrolling interest in subsidiary

-1,063

-1,031

-1,000

-969

-969

-902

-4,438

-821

-810

-798

-788

-771

-756

-742

-741

-710

-686

-660

-634

-611

-585

-553

-522

-490

-463

-435

-410

-385

-357

-329

-313

-287

-258

-226

-200

-173

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest

184,911

267,230

23,356

114,560

181,804

265,849

339,315

399,686

71,819

16,449

-67,388

-59,464

-131,919

-75,182

-72,977

-57,526

-45,006

-31,891

-18,934

-4,524

4,760

16,057

26,708

38,859

20,051

28,206

35,806

39,795

43,532

20,069

24,775

34,169

38,778

45,518

22,759

27,641

Total Liabilities and Stockholders' Equity

594,106

671,722

411,730

477,685

484,574

528,040

612,662

664,173

379,887

155,953

153,359

162,573

52,689

53,124

40,608

56,950

67,641

81,964

91,791

105,779

111,833

26,787

37,815

47,486

26,253

32,784

41,210

47,927

54,386

27,081

31,100

38,635

45,561

52,691

28,858

34,324